Advertisement

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Published on: 

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

Advertisement

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

CheckMate 577 is a randomized, double-blind, phase III study of nivolumab (Opdivo) in the adjuvant setting. Patients with stage I/II esophageal or GEJ cancer that have undergone preoperative chemoradiotherapy (CRT) are randomized to receive either nivolumab or placebo. This is due to the increase in expression of PD-L1 after CRT, says Chau, which has demonstrated survival benefits when combined with nivolumab.

This study is ongoing, with primary endpoints of overall survival and disease-free survival.


Advertisement
Advertisement